hydroxychloroquine has been researched along with Hematologic Malignancies in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD)." | 9.12 | A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. ( Adkins, D; Devine, SM; Dipersio, JF; Fong, T; Goodnough, LT; Graubert, T; Khoury, HJ; Lopez, S; Shenoy, S; Tomasson, M; Trinkaus, K; Vij, R, 2007) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 7.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive lysosomotropic amine that has activity against graft-versus-host disease (GVHD)." | 5.12 | A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. ( Adkins, D; Devine, SM; Dipersio, JF; Fong, T; Goodnough, LT; Graubert, T; Khoury, HJ; Lopez, S; Shenoy, S; Tomasson, M; Trinkaus, K; Vij, R, 2007) |
| "Hydroxychloroquine (HCQ) is an immunosuppressive agent that interferes with antigen presentation and with activity against graft-versus-host disease (GVHD)." | 3.72 | Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. ( Adkins, D; Brown, R; Dipersio, JF; Goodnough, LT; Horowitz, M; Khoury, H; Ma, MK; McLeod, HL; Shenoy, S; Trinkaus, K; Vij, R; Zhang, MJ, 2003) |
| "Hydroxychloroquine was the most frequently used drug for COVID-19." | 2.72 | Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review. ( Kumar Gupta, A; Meena, JP; Mohan Pandey, R; Ram Jat, K; Seth, R; Tanwar, P, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Civriz Bozdağ, S | 1 |
| Cengiz Seval, G | 1 |
| Yönal Hindilerden, İ | 1 |
| Hindilerden, F | 1 |
| Andıç, N | 1 |
| Baydar, M | 1 |
| Aydın Kaynar, L | 1 |
| Toprak, SK | 1 |
| Göksoy, HS | 1 |
| Balık Aydın, B | 1 |
| Demirci, U | 1 |
| Can, F | 1 |
| Özkocaman, V | 1 |
| Gündüz, E | 1 |
| Güven, ZT | 1 |
| Özkurt, ZN | 1 |
| Demircioğlu, S | 1 |
| Beksaç, M | 1 |
| İnce, İ | 1 |
| Yılmaz, U | 1 |
| Eroğlu Küçükdiler, H | 1 |
| Abishov, E | 1 |
| Yavuz, B | 1 |
| Ataş, Ü | 1 |
| Mutlu, YG | 1 |
| Baş, V | 1 |
| Özkalemkaş, F | 1 |
| Üsküdar Teke, H | 1 |
| Gürsoy, V | 1 |
| Çelik, S | 1 |
| Çiftçiler, R | 1 |
| Yağcı, M | 1 |
| Topçuoğlu, P | 1 |
| Çeneli, Ö | 1 |
| Abbasov, H | 1 |
| Selim, C | 1 |
| Ar, MC | 1 |
| Yücel, OK | 1 |
| Sadri, S | 2 |
| Albayrak, C | 1 |
| Demir, AM | 1 |
| Güler, N | 1 |
| Keklik, M | 1 |
| Terzi, H | 1 |
| Doğan, A | 1 |
| Yegin, ZA | 1 |
| Kurt Yüksel, M | 1 |
| Yavaşoğlu, İ | 1 |
| Beköz, HS | 1 |
| Aksu, T | 1 |
| Maral, S | 1 |
| Erol, V | 1 |
| Kaynar, L | 1 |
| İlhan, O | 1 |
| Bolaman, AZ | 1 |
| Sevindik, ÖG | 1 |
| Akyay, A | 1 |
| Özcan, M | 1 |
| Gürman, G | 1 |
| Ünal, Ş | 1 |
| Yavuz, Y | 1 |
| Diz Küçükkaya, R | 1 |
| Özsan, GH | 1 |
| Martín-Moro, F | 1 |
| Marquet, J | 1 |
| Piris, M | 1 |
| Michael, BM | 1 |
| Sáez, AJ | 1 |
| Corona, M | 1 |
| Jiménez, C | 1 |
| Astibia, B | 1 |
| García, I | 1 |
| Rodríguez, E | 1 |
| García-Hoz, C | 1 |
| Fortún-Abete, J | 1 |
| Herrera, P | 1 |
| López-Jiménez, J | 1 |
| Wood, WA | 1 |
| Neuberg, DS | 1 |
| Thompson, JC | 1 |
| Tallman, MS | 1 |
| Sekeres, MA | 1 |
| Sehn, LH | 1 |
| Anderson, KC | 1 |
| Goldberg, AD | 1 |
| Pennell, NA | 1 |
| Niemeyer, CM | 1 |
| Tucker, E | 1 |
| Hewitt, K | 1 |
| Plovnick, RM | 1 |
| Hicks, LK | 1 |
| Moya-Martínez, C | 1 |
| Torre-Castro, J | 1 |
| Fariña-Sabarís, MC | 1 |
| Santiago Sánchez-Mateos, D | 1 |
| Eraña-Tomás, I | 1 |
| Jo-Velasco, M | 1 |
| Requena, L | 1 |
| Meena, JP | 1 |
| Kumar Gupta, A | 1 |
| Tanwar, P | 1 |
| Ram Jat, K | 1 |
| Mohan Pandey, R | 1 |
| Seth, R | 1 |
| Khoury, H | 1 |
| Trinkaus, K | 2 |
| Zhang, MJ | 1 |
| Adkins, D | 2 |
| Brown, R | 1 |
| Vij, R | 2 |
| Goodnough, LT | 2 |
| Ma, MK | 1 |
| McLeod, HL | 1 |
| Shenoy, S | 2 |
| Horowitz, M | 1 |
| Dipersio, JF | 2 |
| Fong, T | 1 |
| Devine, SM | 1 |
| Tomasson, M | 1 |
| Lopez, S | 1 |
| Graubert, T | 1 |
| Khoury, HJ | 1 |
1 review available for hydroxychloroquine and Hematologic Malignancies
| Article | Year |
|---|---|
Clinical presentations and outcomes of children with cancer and COVID-19: A systematic review.
Topics: Antimalarials; Child; COVID-19; Critical Care; Hematologic Neoplasms; Humans; Hydroxychloroquine; Ne | 2021 |
1 trial available for hydroxychloroquine and Hematologic Malignancies
| Article | Year |
|---|---|
A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Chronic Disease; Disease-Free Survival; Double-Blind Method; Female; Graft vs Host Disease; H | 2007 |
5 other studies available for hydroxychloroquine and Hematologic Malignancies
| Article | Year |
|---|---|
Clinical Characteristics and Outcomes of COVID-19 in Turkish Patients with Hematological Malignancies
Topics: Adult; Amides; Azithromycin; Child; COVID-19; Hematologic Neoplasms; Humans; Hydroxychloroquine; Pyr | 2022 |
Survival study of hospitalised patients with concurrent COVID-19 and haematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Co | 2020 |
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
Topics: Adolescent; Adult; Aged; Azithromycin; COVID-19; COVID-19 Drug Treatment; Female; Hematologic Neopla | 2020 |
Cutaneous eruption with reactive endothelial atypia due to emerging targeted cancer therapies: Report of two cases with clinico-pathologic correlation.
Topics: Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Benzothiazoles; Biopsy; Drug Eruptions; Enzyme | 2021 |
Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation.
Topics: Adolescent; Adult; Antigens, CD; Bone Marrow Transplantation; Cause of Death; Enzyme Inhibitors; Gra | 2003 |